Clinical Trials
21 trialsNCT00896376 2026-05-15
Trastuzumab in Treating Women With Metastatic Breast Cancer
Centre Antoine Lacassagne
Phase NA Completed
NCT07095023 2026-04-29
OPTIMAL-BC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase NA Recruiting
NCT02226276 2026-02-13
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
City of Hope Medical Center
Phase NA Active not recruiting
NCT07187752 2025-09-23
Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes
Shandong Cancer Hospital and Institute
Phase NA Not yet recruiting
NCT07115095 2025-08-11
Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer
Shaanxi Provincial Cancer Hospital
Phase NA Completed
NCT06190600 2025-04-30
SPORTNATHy
The Greater Poland Cancer Centre
Phase NA Active not recruiting
NCT06035679 2025-03-12
Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer
First Affiliated Hospital of Fujian Medical University
Phase NA Recruiting
NCT01897441 2024-12-24
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer
Albert Einstein College of Medicine
Phase NA Terminated
NCT04281576 2024-11-14
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
NovoCure Ltd.
Phase NA Completed
NCT05656079 2022-12-19
easy laugh
Shanghai Pudong Hospital
Phase NA Unknown
NCT01295086 2020-11-02
Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer
Odense University Hospital
Phase NA Completed
NCT00496808 2020-09-23
Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast
M.D. Anderson Cancer Center
Phase NA Completed
NCT03756064 2019-08-13
Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer
Zhejiang Cancer Hospital
Phase NA Unknown
NCT03947242 2019-05-15
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.
Henan Cancer Hospital
Phase NA Unknown
NCT03843749 2019-02-18
Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.
Shanghai Changzheng Hospital
Phase NA Unknown
NCT00681993 2019-01-22
PBIC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Completed
NCT00847366 2018-03-15
Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma
AEterna Zentaris
Phase NA Completed
NCT02102438 2016-08-31
Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer
Instituto do Cancer do Estado de São Paulo
Phase NA Withdrawn
NCT01048099 2016-01-29
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase NA Completed
NCT00398437 2013-08-12
Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase NA Unknown
NCT00433407 2012-10-04
T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors
Jonsson Comprehensive Cancer Center
Phase NA Completed